Business, energy, technology, markets and global industry news from Business News Today

Sanofi

PharmaDeviceNews Sanofi
Representative image of neuroimmunology research as Sanofi’s riliprubart Phase 3 trial halt puts CIDP treatment, complement inhibition, and rare neurology drug development under sharper focus.
Pharma & Biotech

Sanofi riliprubart setback puts VITALIZE trial and CIDP strategy under sharper focus

Find out how Sanofi’s riliprubart Phase 3 trial halt could reshape CIDP drug development and complement inhibition strategy.

Read More
Representative image of a rare disease neurology consultation, illustrating how Sanofi’s venglustat FDA priority review could change treatment options for type 3 Gaucher disease.
Pharma & Biotech

Can Sanofi’s venglustat priority review change the treatment outlook for type 3 Gaucher disease?

Sanofi’s venglustat could target neurological type 3 Gaucher disease. The FDA review now tests whether rare disease care can shift.

Read More
Representative image: Scientists analyze CRISPR gene-editing and liver-targeted cardiometabolic research data in a biotech laboratory, reflecting Scribe Therapeutics’ push to advance epigenetic silencing for durable LDL-C reduction.
Pharma & Biotech

Scribe Therapeutics brings specificity challenge into focus for CRISPR cardiometabolic drugs

CRISPR can lower cholesterol. The harder test is whether Scribe can make durability, precision, and scalability work in common disease.

Read More
Lannett’s Lanexa Biologics enters U.S. insulin market with interchangeable LANGLARA approval
Pharma & Biotech

Could LANGLARA finally crack the high-cost insulin access problem in the United States?

Insulin access needs more than approvals. LANGLARA’s real test is whether payers and pharmacies turn interchangeability into savings.

Read More
Pharma & Biotech

Sanofi’s Tzield gains pediatric approval but can early intervention truly change T1D outcomes

FDA expands Tzield use to young children with type 1 diabetes. Discover what this means for early intervention and long-term outcomes.

Read More
Representative image of a biotech conference setting as Innate Pharma heads to the Kempen Life Sciences Conference, where investors are expected to assess the outlook for IPH4502, lacutamab, and monalizumab within the company’s immuno-oncology pipeline.
Pharma & Biotech

What Innate Pharma’s Kempen conference participation reveals about its 2026 biotech strategy

Innate Pharma heads to Kempen as investors assess its oncology pipeline, partnering outlook, and next catalysts. Read the full analysis.

Read More
Pharma & Biotech

How amlitelimab’s dosing flexibility could disrupt biologic treatment patterns in atopic dermatitis

Sanofi’s amlitelimab advances toward filing in atopic dermatitis. Explore how dosing flexibility, durability data, and regional results shape its outlook.

Read More
Representative image of adult vaccine development, highlighting the shift toward simplified dosing and platform innovation as Sanofi expands its immunization strategy.
Features & Analysis

How Sanofi’s CpG 1018 platform could reshape vaccine formulation in 2026

Sanofi's acquisition of CpG 1018 brings TLR9 adjuvants to the forefront. Explore how this could transform combo vaccines and adult immunization strategies.

Read More
Representative image of adult hepatitis B and shingles vaccines, aligned with Sanofi’s acquisition of Dynavax and its push into global adult immunization markets.
Pharma & Biotech

Why Sanofi’s $2.2bn Dynavax deal is a high-stakes bet on adult vaccines

Sanofi to acquire Dynavax for $2.2B to boost adult vaccines. Find out how HEPLISAV-B and Z-1018 fit into Sanofi’s global immunization strategy.

Read More
Pharma & Biotech

GSK’s Exdensur wins FDA nod for severe asthma: Can twice-yearly dosing reset the biologics playbook?

GSK’s Exdensur has been approved by the FDA as the first biannual biologic for severe asthma. Find out what this means for patients, payers, and rivals.

Read More